文献速递慢性肾脏病血液净化与透析

慢性肾脏病患者血磷控制策略

Strategies for Phosphate Control in Patients With CKD.
PubMed 文献 · Kidney Int Rep · 2019-06-20

本综述讨论慢性肾脏病(CKD)患者高磷血症的治疗策略,包括限制饮食磷摄入、减少肠道磷吸收、透析清除磷及管理肾性骨营养不良。文章指出血磷受肾、肠、骨及内分泌系统复杂调控,食品添加剂磷是CKD重要因素,尽管多管齐下,许多患者血磷仍难达标,且降低血磷对硬终点获益仍存争议。

要点

  • CKD患者高磷血症常见,尤其透析患者,与不良结局和死亡风险相关。
  • 血磷稳态依赖肾、肠、骨及内分泌系统复杂调控,食品添加剂磷是重要因素。
  • 降磷治疗包括饮食限磷、减少肠道吸收、透析清除和管理肾性骨营养不良。

核心结论

  • CKD患者高磷血症管理困难,多措施联合下许多患者仍不达标。
  • 降低血磷对硬临床结局的获益在干预试验中仍存争议。

研究设计与样本

  • 综述,讨论CKD患者高磷血症的现有治疗策略及其实践挑战与利弊。

主要发现

  • 观察性流行病学研究将血磷升高与不良结局和较高死亡风险相关联。
  • 实验数据支持磷在骨和心血管疾病发展中的作用。
  • 饮食磷来源及工业化食品中磷添加剂在CKD中尤为重要。

临床怎么用

  • 临床可综合采用饮食限磷、减少肠道磷吸收、透析清除磷及管理肾性骨营养不良。
  • 需关注食品添加剂磷的来源及其对CKD患者的影响。

局限性

  • 降低血磷对硬临床结局的获益尚存争议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hyperphosphatemia is a common complication in patients with chronic kidney disease (CKD), particularly in those requiring renal replacement therapy. The importance of controlling serum phosphate has long been recognized based on observational epidemiological studies that linked increased phosphate levels to adverse outcomes and higher mortality risk. Experimental data further supported the role of phosphate in the development of bone and cardiovascular diseases. Recent advances in our understanding of the mechanisms involved in phosphate homeostasis have made it clear that the serum phosphate concentration depends on a complex interplay among the kidneys, intestinal tract, and bone, and is tightly regulated by a complex endocrine system. Moreover, the source of dietary phosphate and the use of phosphate-based additives in industrialized foods are additional factors that are of particular importance in CKD. Not surprisingly, the management of hyperphosphatemia is difficult, and, despite a multifaceted approach, it remains unsuccessful in many patients. An additional issue is the fact that the supposedly beneficial effect of phosphate lowering on hard clinical outcomes in interventional trials is a matter of ongoing debate. In this review, we discuss currently available treatment approaches for controlling hyperphosphatemia, including dietary phosphate restriction, reduction of intestinal phosphate absorption, phosphate removal by dialysis, and management of renal osteodystrophy, with particular focus on practical challenges and limitations, and on potential benefits and harms.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Barreto FC, Barreto DV, Massy ZA, et al. Strategies for Phosphate Control in Patients With CKD. Kidney Int Rep. 2019. PMID: 31440695. doi:10.1016/j.ekir.2019.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。